<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611528</url>
  </required_header>
  <id_info>
    <org_study_id>ECO HoFH-2022-01</org_study_id>
    <nct_id>NCT05611528</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia</brief_title>
  <official_title>Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia in a Real Life Setting in Canada</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel Gaudet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ecogene 21</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study designed to evaluate the long-term safety and efficacy of&#xD;
      evinacumab, a fully human ANGPTL3 antibody, in patients with homozygous familial&#xD;
      hypercholesterolemia (HoFH), in a real-life setting in Canada.&#xD;
&#xD;
      Eligible patients for this study are male and female adult patients with HoFH. Evinacumab&#xD;
      will be added on top of the patient's background lipid-modifying therapy (LMT), including&#xD;
      statins, ezetimibe, PCSK9 inhibitors, lomitapide or other lipid lowering therapies. This&#xD;
      study will be conducted using an hybrid (on-site, foldable sites) approach. Patients will&#xD;
      enter the current study, in an open-label treatment period, following their screening. This&#xD;
      study will continue until reimbursement of evinacumab in Canada or for a maximum of 24&#xD;
      months. The end of study (EoS) visit will be scheduled 4 weeks after the last dose has been&#xD;
      injected and will be followed by a 52-week follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2023</start_date>
  <completion_date type="Anticipated">February 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lipid profile</measure>
    <time_frame>Every 4 weeks up to 2 years</time_frame>
    <description>Change in total cholesterol, LDL-Cholesterol, HDL-Cholesterol, triglyceride, non-HDL-Cholesterol and apolipoprotein B plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in aspartate transaminase (AST) plasma concentration</measure>
    <time_frame>Every 4 weeks up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change in alanine aminotransferase (ALT) plasma concentration</measure>
    <time_frame>Every 4 weeks up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipoprotein (a)</measure>
    <time_frame>Yearly up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete blood count</measure>
    <time_frame>Every 12 weeks up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total bilirubin</measure>
    <time_frame>Every 12 weeks up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatine phosphokinase</measure>
    <time_frame>Every 12 weeks up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Homozygous Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Evinacumab-treated patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evinacumab</intervention_name>
    <description>Evinacumab 15 mg/kg administered intravenously every 4 weeks</description>
    <arm_group_label>Evinacumab-treated patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HoFH patients having been previously or being currently treated with evinacumab or&#xD;
             clinical diagnosis of HoFH requiring additional lipid lowering therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any new condition or worsening of an existing condition, which in the opinion of the&#xD;
             investigator would make the patient unsuitable for enrollment, or could interfere with&#xD;
             the patient participating in or completing the study;&#xD;
&#xD;
          -  Pregnant or breastfeeding women;&#xD;
&#xD;
          -  Women of childbearing potential who are unwilling to practice highly effective&#xD;
             contraception prior to the initial dose/start of the first treatment, during the&#xD;
             study, and for at least 24 weeks after the last dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Diane Brisson, PhD CCRP</last_name>
    <phone>418-545-1252</phone>
    <email>diane.brisson@ecogene21.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ecogene-21</name>
      <address>
        <city>Saguenay</city>
        <state>Quebec</state>
        <zip>G7H 7K9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyne Côté, RN</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>October 31, 2022</study_first_submitted>
  <study_first_submitted_qc>November 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>March 2, 2023</last_update_submitted>
  <last_update_submitted_qc>March 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ecogene 21</investigator_affiliation>
    <investigator_full_name>Daniel Gaudet</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>ANGPTL3</keyword>
  <keyword>Real-life study</keyword>
  <keyword>Monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

